Back to Authors

Shet, Tanuja

Mayo Clinic

Tata Memorial Hospital

Citations 1

IL-17A potentiates malignant T-cell viability via electron transport chain complex I in cutaneous T-cell lymphoma
Attrish, Diksha , Dhamija, Bhavuk , Mukherjee, Ditipriya , Sawant, Vinanti , Marathe, Soumitra , Saul, Dominik , Basu, Moumita , Banik, Ankit , Sharma, Neha , Shet, Tanuja, Jain, Hasmukh , Sharma, Priyanka , Purwar, Rahul , Saul, Dominik , Kosinsky, Robyn Laura

No container title available | May 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.21.655309 Get It

Abstract Cutaneous T-cell lymphoma (CTCL) is a rare malignancy of skin-resident T cells characterized by an aberrant cytokine profile, notably elevated Interleukin-17A (IL-17A) levels. However, the functional importance of IL-17A dysregulation in the CTCL pathogenesis remains poorly understood. Our analysis revealed increased IL-17A receptor (IL-17RA) expression in CTCL patient samples, supporting the importance of IL-17A signaling in CTCL progression. Proteomic and metabolomic profiling of IL-17A-treated malignant T cells revealed mitochondrial electron transport chain (ETC) complex I as a key downstream target of IL-17A signaling. Furthermore, we confirmed the elevated expression of ETC complex I in CTCL patient samples compared to healthy control T cells, hence highlighting the clinical relevance of the IL-17A signaling-ETC complex 1 axis. Altogether, our data unveil the function of IL-17A signaling in the metabolic axis in CTCL progression, which could be useful for developing advanced therapeutic strategies. Significance statement: We uncover an IL-17A-induced electron transport chain (ETC) complex I pro-tumorigenic circuit and provide proof of concept evidence that ETC complex I can be targeted to combat the challenges posed by Cutaneous T-cell Lymphoma aggressiveness.